Parkinson's Disease (PD)

Parkinson’s disease (PD) is a neurodegenerative disease characterized by motor deficits including rigidity, tremor, bradykinesia, abnormal gait and difficulty walking. Loss of nigrostriatal dopaminergic neurons and the presence of α synuclein-containing Lewy bodies are neuroanatomical hallmarks of the disease. PD can be idiopathic or genetic in nature, and mutations in several genes have been associated with an increased risk for the disease. Specifically, mutations in leucine-rich repeat kinase 2 (Lrrk2), Parkin (Park2), PTEN induced putative kinase 1 (Pink1) and DJ-1 (Park7) have all been implicated as causative for PD; however, the mechanisms by which they contribute to PD have yet to be elucidated.

To help aid in the understanding of these genes and provide more relevant models of PD, Horizon, in collaboration with The Michael J. Fox Foundation, has created the first targeted knockout rat models for these gene targets.

Request more information

Parkinson's Disease Animal Models

Parkinson's Knockout Rats

Parkinson's brochure

Parkinson's Models Publications

  • Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease
  • Early Expression of Parkinson’s Disease-Related Mitochondrial Abnormalities in PINK1 Knockout Rats
  • Surfactant Secretion in LRRK2 Knock-Out Rats: Changes in Lamellar Body Morphology and Rate of Exocytosis
  • Abrogation of α-synuclein–mediated dopaminergic neurodegeneration in LRRK2-deficient rats
  • STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson’s disease
  • Leucine-Rich Repeat Kinase 2 (LRRK2-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis
  • Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs
  • Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies
  • Regulation of dopamine presynaptic markers and receptors in the striatum of DJ-1 and Pink1 knockout rats
  • Liposomal-formulated curcumin [Lipocurc™] targeting HDAC (Histone Deacetylase) prevents apoptosis and improves motor deficits in Park 7 (DJ-1)-knockout rat model of Parkinson’s disease: implications for epigenetics-based nanotechnology-driven drug platform
  • A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson’s Research
  • Evidence for early and progressive ultrasonic vocalization and oromotor deficits in a PINK1 gene knockout rat model of Parkinson's disease
  • Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors
Back to top